Urgent Notice to All Conference Participants

It has been brought to our attention that EHS Housing has recently been cold calling our speakers offering accommodation for a named Fusion conference. Please note that we have no association with EHS Housing and they are acting on our behalf without our permission. We strongly advise that any calls from EHS Housing are ignored or ended immediately. If you are contacted by EHS Housing, please notify us immediately.

All Fusion registration fees are inclusive of accommodation (for three fixed nights) and reservations are handled internally, entirely by Fusion Conferences. If you have any questions concerning your accommodation, please contact Fusion Conferences directly via admin@fusion-conferences.com.

Home > Past Conferences > Nuclear Receptors Conference

The registration process for this conference has now closed.

Registration Deadlines

Early bird – expired

Talk Submission – expired

Poster Submission – expired

Last Chance – expired

Nuclear Receptors Conference

New Roles for Nuclear Receptors in Development, Health and Disease

27 Feb 2018 - 02 Mar 2018

Cancun, Mexico

Synopsis

This conference has now passed however, the following meetings may be of interest;
3rd Exploring DNA Repair Pathways as Targets for Cancer Therapy Conference | 23 - 26 Feb 2019 | Nassau, The Bahamas

Nuclear Receptors are, physiologically and pharmacologically, a critical superfamily of transcription factors. They drive key processes at every stage from development and reproduction to ageing and cancer. They are critical determinants of everyday health via their roles in metabolism and circadian rhythms. Nuclear receptors allow external factors to influence cellular pathways and the fact that many bind and are activated by small molecules means they represent highly druggable targets; currently, 13% of FDA-approved drugs target nuclear receptors.

This meeting will address the new roles and novel crosstalk mechanisms that are emerging for many of the 48 human nuclear receptors, in health and disease. For example, it has long been known that the estrogen receptor drives progression of breast cancer, and patients with estrogen receptor-positive disease are treated using antiestrogens or aromatase inhibitors to inhibit estrogen signalling. Now however, it is apparent that the androgen receptor can in some cases drive breast cancer progression and is a therapeutic target, resulting in clinical trials for androgen receptor-targeting therapies in advanced breast cancer. The androgen receptor, itself long the main therapeutic target in prostate cancer, is emerging as a key player in metabolic disease, while conversely other nuclear receptor including the glucocorticoid receptor and several orphan nuclear receptors are implicated in prostate cancer progression. Meanwhile, given the impact of many nuclear receptors on the central nervous system, it is unsurprising that they are being explored in the context of neurological disorders and depression. Thus there is wide scope for re-purposing of licensed drugs and development of new NR-targeting therapies for a host of conditions and diseases.

Crosstalk between nuclear receptors and other fundamental processes is another exciting expanding area that will also be covered. DNA damage repair pathways are inextricably linked to steroid signalling via transcriptional processes, with implications for drug combinations in several diseases. Hitherto unsuspected roles of nuclear receptors in epigenetic control and the processing and function of non-coding RNAs opens up to capacity of this superfamily to further means of impacting on development and normal functioning, but also on disease development. 

This unique meeting will bring together many of the leading figures in nuclear receptor research from across the globe, to discuss emerging roles and their implications for health and disease – and both human and drug development – in an intimate meeting that will generate meaningful idea exchange and interaction that will help to further shape this influential field.

Join the conference LinkedIn group to keep up to date with announcements and latest news concerning the conference.

Key Sessions

  • Further emerging roles for nuclear receptors in cancer
  • Structural insights into nuclear receptor function and crosstalk
  • Nuclear receptors’ role in epigenetic regulation and non coding RNA
  • Nuclear receptors and DNA damage
  • Nuclear receptors and cell cycle
  • Nuclear receptors in metabolism/metabolic disease
  • Nuclear receptors in the CNS

Target Audience

Scientists and Clinician Scientists at a range of levels from postdoctoral and up: Principal Investigators, Junior Team Leaders, Research Fellows. Ambitious postgraduate students in the field will also be encouraged to attend.

Relevant specialties are wide-ranging, reflecting the importance of nuclear receptors in many aspects of health and disease. These include Endocrinology, Oncology, Paediatrics, Urology, Gynaecology, Obstetric Medicine, Neuroscience, Cardiology.

Learning Objectives 

  1. Introduce the newest advances, in discovery and methodology in the field of Nuclear Receptor research to a wide audience, through oral and poster presentation with both formal and informal discussion.
  2. Develop a deeper understanding of the latest advances in our knowledge of nuclear receptor biology at all levels (structural, transcriptional, cross-talk with each other and with different pathways) and the subsequent effects on development, reproduction and disease.
  3. Consider and possibly extend the evidence base for re-purposing of nuclear receptor-targeting therapies
  4. Provide an environment for cross-talk and cross-fertilisation between all Nuclear Receptor-related disciplines (reproduction, fertility, neuroscience, oncology, structural biology, transcription) allowing the different disciplines to learn from each other and forge new collaborations
  5. Celebrate over 30 years of Nuclear Receptor research while discussing the next challenges in the field and how we can address them.

Student Grants

We currently have 3 x $800 student grants available for the conference to help offset the cost of registration. If this is of interest to you, please send the following to Meredith@fusion-conferences.com by 15th January 2018

  • Name and brief description of your current research
  • Why you would benefit from attend
  • An abstract for poster consideration

Student Offer

Take advantage of this fantastic opportunity for students! Register an academic at the standard rate of $1,798.00 and bring a student for only $745. Unfortunately, Postdocs are not eligible. Both registration packages include; accommodation for the 27th February, 28th February and 1st March 2018 (on a shared basis for students, note guest rooms are open plan) and a 24hour all-inclusive food and beverage package for the conference period. Once you have registered and paid in full, please contact Meredith Willmott (Meredith@fusion-conferences.com) to obtain a special registration link for your student.

Publishing Opportunity

We are delighted to be working with Bioscientifica publishing house to publish abstracts from the Nuclear Receptors Conference, 27th February – 02nd March 2018 in Cancun, Mexico. Bioscientifica publishes many of the leading journals and online products in endocrinology on behalf of, and in collaboration with, key endocrine societies worldwide. They provide permanent, citable, free-to-read records of meeting abstracts, ensuring the content from an event remains discoverable and available in perpetuity, prolonging the life of the event.

If consent is given abstracts from speakers, oral presenters and poster presenters will be published. Please see the Bioscientifica website for more information about them.

If you would like your abstract to be published, please provide consent by confirming via email (meredith@fusion-conferences.com). Please note this opportunity is not mandatory we will only publish abstracts if consent has been given. 

Confirmed Plenary Speakers

Geoffrey Greene (The University of Chicago)
UNDERSTANDING AND EXPLOITING STEROID RECEPTOR CROSS TALK IN HORMONE SENSITIVE CANCERS

Bert O'Malley (Baylor College of Medicine)
NUCLEAR RECEPTORS AND THEIR COACTIVATORS: AN ENTRE TO UNDERSTANDING HUMAN DISEASES

David Moore (Baylor College of Medicine)

Confirmed Invited Speakers

Suzanne Conzen (The University of Chicago)
MODULATING GLUCOCORTICOID RECEPTOR FUNCTION IN BREAST AND PROSTATE CANCER

Frank Claessens (University of Leuven)
DIRECT AND INDIRECT EFFECTS OF ANDROGENS ON THE MUSCULOSKELETAL SYSTEM

Scott Dehm (University of Minnesota)
CLINICALLY-RELEVANT CONTEXTS FOR AR VARIANTS IN PROSTATE CANCER

Theresa Hickey (The University of Adelaide)

Lee Kraus (The University of Texas Southwestern Medical Center)
NUCLEAR RECEPTORS, TRANSCRIPTIONAL ENHANCERS, AND GENE REGULATION

Luca Magnani (Imperial College London)
MAPPING THE EPIGENOME OF BREAST CANCER PATIENTS TO EXPOSE NEW MECHANISMS OF ENDOCRINE THERAPY RESISTANCE

Susanne Mandrup (University of Southern Denmark)
TRANSCRIPTIONAL NETWORKS REGULATING MSC DIFFERENTIATION

Sebastiaan Meijsing (Max Planck Institute for Molecular Genetics)
TRANSCRIPTIONAL REGULATION BY THE GLUCOCORTICOID RECEPTOR: ROLE OF DNA SHAPE AND SEQUENCE IN MODULATING OUTPUT AND NOISE

Eric Ortlund (Emory University)
TARGETING LRH-1 WITH SMALL MOLECULE MODULATORS

Steffi Oesterreich (Women's Cancer Research Institute)

Eva Estébanez-Perpiñá (University of Barcelona)
ANDROGEN RECEPTOR DIMERIZATION

David Ray (The University of Manchester)
RAPID, CYTOPLASMIC ACTIONS OF THE GLUCOCORTICOID RECEPTOR IMPACT ON CELL MOVEMENT

Ganesh Raj (University of Texas Southwestern Medical Center)

Yijun Ruan (The Jackson Laboratory)

Philippa Saunders (University of Edinburgh)
ANDROGENS AND ENDOMETRIAL FUNCTION: REPLICATION, REPAIR AND REGENERATION

Carol Sartorius (University of Colorado)
PROGESTERONE RECEPTOR REGULATION OF CANCER CELL TRANSLATION

John Schwabe (University of Leicester) 

Carlie de Vries (University of Amsterdam)
NUR77 GOES METABOLIC IN MACROPHAGES

Catherine Williamson (King's College London)
GESTATIONAL METABOLIC ADAPTATIONS SIGNALLED THROUGH NUCLEAR RECEPTORS

Wilbert Zwart (Netherlands Cancer Institute)
ESTROGEN RECEPTOR CISTROMICS IN BREAST TUMORS: FROM BIOMARKERS TO NOVEL DRUG TARGETS




Sponsors

Sponsors

Report

New Roles for Nuclear Receptors in Health, Development & Disease

Cancun, Feb 27th - March 02nd 2018

This new major meeting, focussing on recent breakthroughs and insights in Nuclear Receptor Biology, took place in Cancun, Mexico from Feb 27th to March 2nd 2018. It had a broad remit, to cover how nuclear receptors shape development and contribute to health as well as how their dysfunction and dysregulation can cause disease - and importantly how we can exploit them therapeutically. The attendance reflected this breadth, with scientists and clinicians whose research areas included fertility, oncology, cardiology, endocrinology, ageing, neuroscience, reproduction and metabolism. The meeting was chaired by an international panel consisting of Charlotte Bevan and Simak Ali (Imperial College, London, UK), Karen Knudsen (Sidney Kimmel Cancer Center and University of Philadelphia, USA) and Wayne Tilley (University of Adelaide, Australia).

As the inaugural Fusion Nuclear Receptor meeting, a keynote address, sponsored by Cancer Research UK, was given by the “Father of molecular endocrinology”, Bert O’Malley (Baylor College of Medicine). He gave an overview of the history of the field, encompassing the first work on steroid hormones, the cloning of their receptors, right up to his current exciting work on nuclear receptor cofactors in disease and therapy.

The rest of the meeting divided into relevant subject areas, although inevitably there was a lot of cross-talk and cross-fertilisation between sessions. Day 1 began with a wide-ranging session on “NR in Development, Metabolism and Reproduction”. The first speaker, David Moore (Baylor) gave an authoritative and thought-provoking plenary on how the receptors PPARalpha and FXR act and compete in the liver to regulate liver energy, and later in the session these receptors came up again in Catherine Williamson’s (King’s College, London) talk on metabolic adaptations in gestation and David Volle’s (Clermont) on NR networks in male fertility. Carlie de Vries (Denmark) described how the orphan receptor Nurr77 links inflammatory response and mitochondrial metabolism in macrophages. Ying Zhou (Baylor) discussed Vitamin D receptor regulation of macrophages in the liver and Kendall Nettles (Scripps) described systems biology discovery of new roles for GR in skeletal muscle. Exciting data was also presented on roles of “sex steroid” receptors, AR and ER, in non-reproductive tissue (Muscle and brain) in talks by Frank Claessens (Leuven) and Charlotte Cornil (Liege). The session closed with a fast-paced panel discussion, led ably by the session chairs and involving all the speakers and many of the audience. This set the tone for these panel discussions which were a well-received and a stimulating feature of the meeting as a whole.

Day 2 began with the hot topic of nuclear receptor crosstalk. Three of the talks (Karen Knudsen (Philadelphia), Dan Gioeli (Virginia) and Claire Fletcher (Imperial College discussed the issue of NR crosstalk with DNA damage repair pathways, while Theresa Hickey (Adelaide), Suzanne Conzen (Chicago) and Wilbert Zwart (NKI) dealt with NR-NR crosstalk. Both of these have enormous implications for cancer therapy, and the question of synthetic lethality and how this translates to patients was hotly debated in the panel discussion. The afternoon session went on to Epigenetics & Chromatin Regulation – by and of NRs – and it covered enhancer RNAs (Lee Kraus (UTSW) and Luca Magnani (Imperial)), transfer RNAs (Jessica Finley-Schultz (Colorado)), microRNAs (Charlotte Bevan (Imperial)) and the importance of genomic 3D structure on transcriptional regulation (Yijun Ruan, Jackson Laboratory). The latter topic was picked up again on Day 3 in the session on Structure and Regulation, by Sebastiaan Meijsing (Max Planck Inst). This session also included several speakers on NR structure, (Eric Ortlund (Emory), Eva Estebanez-Perpina (Barcelona) Isabelle Billas (IGBMC), Eric Kalkhoven (Utrecht) and John Schwabe (Leicester). This is a controversial subject on which some disagreements are evident in the field, providing a great deal of discussion. We also heard how mutations alter NR structure and functional, from Geoff Greene (Chicago) and Steffi Osterreich (Pittsburgh).

Session 4, on NR in Non-Malignant Disorders, was kicked off by Philippa Saunders (Edinburgh), an authority on steroids in the female reproductive system, who talks about androgens in the endometrium; endometriosis was also discussed by Sang Jun Han (Baylor) in the context of ERbeta. Toshiya Tanaka (Tokyo) presented interesting work on PPARalpha ligands for non-alcoholic fatty liver disease. Fascinating talks were given by David Ray (Manchester) on nongenomic actions of GR, with implications in development, Susanne Mandrup (Southern Denmark) on differentiation of mesenchymal stem cells, Ines Pineda-Torra (UCL) on Liver X Receptor in metabolic disease and Pamela England with her work on Nurr1 as a potential drug target in Parkinson’s disease

The final session on NR in cancer picked up on some of the themes from previous talks, with Amy Mandigo (Jefferson) discussing AR interactions with Rb and E2F1 signalling in prostate cancer, while Gordon Hager showed his fascinating work concerning tracking transcriptional regulation in real time. Scott Dehm (Minnesota) talked about truncated AR variants and their significance in prostate cancer, while Ganesh Raj (UTSW) described new ways to target a so-called “orphan” receptor in breast cancer and Amina Zoubeidi (Vancouver) described less specific ways of inhibiting androgen signalling in prostate cancer to prevent cell plasticity.

Two poster viewings were held (days 1 and 3) and poster judges were drawn from the speakers: the awards went to 3 early-career researchers who were also well represented in the oral presentations. The attendance at all sessions was close to 100%, typical of the collaborative and collegiate atmosphere at the meeting. Panel discussions were frank and inclusive, and indeed were continued into he social aspects of the meeting, which again illustrated the friendly and inclusive atmosphere. The feeling was overwhelmingly that this was a hugely useful and timely meeting which should be revisited in 2020. The breadth of the programme and speakers was acknowledged to be unique and a positive reason why so many would enthusiastically return, in additional to the opportunities for networking with so many key researchers in an intimate meeting. The venue and professional, friendly and effective organisation by Fusion Conferences were also felt to be major contributing factors to the meeting’s success. The free time in the afternoons, whether with colleagues on arranged tours, or informal activities at the resort, enhanced networking and were greatly appreciated by all attendees.

The meeting was made possible by generous support from Gold sponsors Janssen, Bronze sponsors the Society for reproduction & Fertility and Cancer Research UK, and endorsing partners Society for Endocrinology and Journal of Molecular Endocrinology.

Programme

TUESDAY 27th FEBRUARY 2018

14:00 – 14:45

Registration & Reception

14:00 – 14:45

Group Welcome Lunch
*Kalmia Buffet Restaurant*

14:45 – 15:00

Opening Comments

NR in Development, Metabolism and Reproduction
Session Chairs: Wayne Tilley and Isabelle Billas

15:00 – 15:45

David Moore
Baylor College of Medicine

REGULATION OF LIVER ENERGY BALANCE BY PPARALPHA AND FXR

15:45 – 16:15

Carlie de Vries
University of Amsterdam

NUR77 GOES METABOLIC IN MACROPHAGES

16:15 – 16:45

Frank Claessens
University of Leuven

DIRECT AND INDIRECT EFFECTS OF ANDROGENS ON THE MUSCULOSKELETAL SYSTEM

16:45 – 17:15

Charlotte Cornil
University of Liege

ESTROGEN NUCLEAR- AND MEMBRANE-INITIATED SIGNALING COOPERATE TO REGULATE BEHAVIOR

17:15 – 17:45

Refreshment Break

17:45 – 18:15

Catherine Williamson
King's College London

GESTATIONAL METABOLIC ADAPTATIONS SIGNALLED THROUGH NUCLEAR RECEPTORS

18:15 – 18:30

Kendall Nettles
The Scripps Research Institute 

CHEMICAL SYSTEMS BIOLOGY ANALYSES REVEAL DISSOCIATED GLUCOCORTICOID SIGNALING NETWORKS IN SKELETAL MUSCLE

18:30 – 18:45

Ying Zhou
Baylor College of Medicine

VITAMIN D RECEPTOR REGULATES TISSUE MACROPHAGE ACTIVITY IN PRESPONSE TO HEPATIC ENDOPLASMIC RETICULUM STRESS

18:45 – 19:15

David Volle
Université Clermont Auvergne

NUCLEAR RECEPTOR NETWORKS IN MALE FERTILITY

19:15 – 19:45

PM Panel Discussion

19:45 – 20:15

Poster Viewing & Drinks

20:15

Group Dinner

WEDNESDAY 28th FEBRUARY 2018

07:00 – 08:30

Breakfast
*Kalmia Buffet Restaurant*

NR Crosstalk

Session Chairs: Sylvie Mader and Eric Kalkhoven

08:30 – 09:15

Karen Knudsen
Thomas Jefferson University

TARGETING DNA REPAIR-AR CROSSTALK DYSFUNCTION IN ADVANCED PROSTATE CANCER

09:15 – 09:30

Daniel Gioeli
University of Virginia

CHECKPOINT KINASE 2 AND ANDROGEN RECEPTOR CROSS-­TALK REGULATE THE DDR AND PROSTATE CANCER GROWTH

09:30 – 10:00

Theresa Hickey
The University of Adelaide

ANDROGEN AND ESTROGEN RECEPTORS IN BREAST TISSUES: OPPONENTS OR TEAMMATES?

10:00 – 10:30

Refreshment Break

10:30 – 11:00

Wilbert Zwart
Netherlands Cancer Institute

ESTROGEN RECEPTOR CISTROMICS IN BREAST TUMORS: FROM BIOMARKERS TO NOVEL DRUG TARGETS

11:00 – 11:30

Suzanne Conzen
The University of Chicago

MODULATING GLUCOCORTICOID RECEPTOR FUNCTION IN BREAST AND PROSTATE CANCER

11:30 – 11:45

Claire Fletcher
Imperial College London

MIR-346 INTERACTION WITH A LONG NON-CODING RNA LINKS AR ACTIVITY AND DNA DAMAGE REPAIR.

11:45 – 12:15

AM Panel Discussion

12:15 – 16:15

Lunch at Leisure & Free Time

12:30 – 15:45

Group Trip: Snorkeling (signups required in advance)

Epigenetics & Chromatin Regulation
Session Chairs:
Claire Fletcher and Daniel Gioeli  

16:15 – 16:45

Lee Kraus
University of Texas Southwestern Medical Center

NUCLEAR RECEPTORS, TRANSCRIPTIONAL ENHANCERS, AND GENE REGULATION

16:45 – 17:15

Luca Magnani
Imperial College London

ENHANCERS MAPPING UNCOVERS PHENOTYPIC HETEROGENEITY AND EVOLUTION IN PATIENTS WITH LUMINAL BREAST CANCER

17:15 – 17:45

Charlotte Bevan
Imperial College London

MICRORNA REGULATION OF ANDROGEN SIGNALLING

17:45 – 18:15

Yijun Ruan
The Jackson Laboratory

PROTEIN FACTORS INVOLVED IN 3D GENOME ORGANIZATION & TRANSCRIPTION REGULATION

18:15 – 18:45

Jessica Finlay-Schultz
University of Colorado

PROGESTERONE RECEPTOR REGULATION OF CANCER CELL TRANSLATION

18:45 – 19:15

PM Panel Discussion

19:15 – 19:45

Refreshment Break

19:45 – 20:45

Bert O’Malley: Cancer Research UK plenary speaker
Baylor College of Medicine

NUCLEAR RECEPTORS AND THEIR COACTIVATORS: AN ENTRE TO UNDERSTANDING HUMAN DISEASES

20:45

Dinner at Leisure

THURSDAY 1st MARCH 2018

07:00 – 08:30

Breakfast
*Kalmia Buffet Restaurant*

NR structure & regulation
Session Chairs: Moray Campbell and Pamela England

08:30 – 09:15

Geoffrey Greene
The University of Chicago

EXPLOITING MULTIPLE NUCLEAR RECEPTORS IN BREAST CANCER

09:15 – 09:45

Steffi Oesterreich
University of Pittsburgh

ER MUTATIONS IN ENDOCRINE RESISTANT BREAST CANCER

09:45 – 10:15

Eric Ortlund
Emory University 

TARGETING LRH-1 WITH SMALL MOLECULE MODULATORS

10:15 – 10:45

Sebastiaan Meijsing
Max Planck Institute for Molecular Genetics

TRANSCRIPTIONAL REGULATION BY THE GLUCOCORTICOID RECEPTOR: ROLE OF DNA SHAPE AND SEQUENCE IN MODULATING OUTPUT AND NOISE

10:45 – 11:15

Refreshment Break

11:15 – 11:45

Eva Estébanez-Perpiñá
University of Barcelona

ANDROGEN RECEPTOR DIMERIZATION

11:45 – 12:00

Eric Kalkhoven
Utrecht University

NATURAL PPARγ MUTANTS: A MODEL FOR ALLOSTERIC SIGNALING BETWEEN NUCLEAR RECEPTORS AND DNA

12:00 – 12:15

Isabelle Billas
IGBMC

STRUCTURAL BASIS OF SPECIFIC DNA RECOGNITION BY THE ESTROGEN-RELATED RECEPTOR ERR

12:15 – 12:45

John Schwabe

University of Leicester

STRUCTURAL BIOLOGY TO UNDERSTAND CO-REGULATOR MECHANISMS, NUCLEAR RECEPTOR DISEASE AND TO DEVELOP NOVEL THERAPEUTIC APPROACHES

12:45 – 13:15

AM Panel Discussion

13:15 – 15:30

Lunch at Leisure & Free Time

NR in non-malignant disorders  

Session Chairs: Amina Zoubeidi and Douglas Gibson

15:30 – 16:00

Philippa Saunders
The University of Edinburgh

ANDROGENS AND ENDOMETRIAL FUNCTION: REPLICATION, REPAIR AND REGENERATION

16:00 – 16:15

Pamela England
University of California, San Francisco

DE-ORPHANING AND DRUGGING NURR1 – A THERAPEUTIC TARGET FOR PARKINSON’S DISESASE

16:15 – 16:45

David Ray
The University of Manchester

RAPID, CYTOPLASMIC ACTIONS OF THE GLUCOCORTICOID RECEPTOR IMPACT ON CELL MOVEMENT

16:45 – 17:00

Sang Jun Han
Baylor College of Medicine

THE PATHOGENIC ROLE OF ESTROGEN RECEPTOR ΒETA DRIVES IN ENDOMETRIOSIS

17:00 – 17:30

Refreshment Break

17:30 – 18:00

Susanne Mandrup
University of Southern Denmark

TRANSCRIPTIONAL NETWORKS REGULATING MSC DIFFERENTIATION

18:00 – 18:15

Toshiya Tanaka 
The University of Tokyo

PEMAFIBRATE, A SELECTIVE PPARΑ MODULATOR (SPPARMΑ), PREVENTS INTRAHEPATIC MACROPHAGE ACCUMULATION AND ACTIVATION OF NON-ALCOHOLIC STEATOHEPATITIS

18:15 – 18:30

Ines Pineda-Torra
University College London

BEYOND LIGAND ACTIVATION: DISRUPTING LXRΑ PHOSPHORYLATION TO REPROGRAM DIETINDUCEDTRANSCRIPTOMES AND MODULATE PROGRESSION OF METABOLIC DISEASES

18:30 – 19:00

PM Panel Discussion

19:00 – 20:00

Poster Session & Refreshments

20:00

*Gala Dinner & Poster Awards*

FRIDAY 2nd MARCH 2018

07:00 – 08:30

Breakfast
*Kalmia Buffet Restaurant*

NR in cancer
Session Chairs: Ines Pineda-Torra and Wilbert Zwart

08:30 – 09:00

Gordon Hager
National Cancer Institute

THE STRUCTURAL BASIS OF CHROMATIN REPROGRAMMING BY STEROID RECEPTORS

09:00 – 09:15

Moray Campbell
The Ohio State University

STAGE-SPECIFIC AND GLOBAL FUNCTIONS OF NCOR2 IN PROSTATE CANCER PROGRESSION

09:15 – 09:45

Scott Dehm
University of Minnesota

CLINICALLY-RELEVANT CONTEXTS FOR AR VARIANTS IN PROSTATE CANCER

09:45 – 10:15

Refreshment Break

10:15 – 10:45

Ganesh Raj
University of Texas Southwestern Medical Center

TARGETING THE INTERACTOME OF AN ORPHAN NUCLEAR RECEPTOR IN TRIPLE NEGATIVE BREAST CANCER

10:45 – 11:00

Amina Zoubeidi
University of British Columbia

RATIONALE TARGETING CELL PLASTICITY IN TREATMENT RESISTANT PROSTATE CANCER

11:00 – 11:15 

Sylvie Mader
Université de Montréal

ROLE OF CHROMATIN REMODELING IN THE SUPPRESSION OF ESTROGEN-INDUCED TRANSCRIPTION BY PURE ANTIESTROGENS

11:15 – 11:30

Amy Mandigo
Thomas Jefferson University

RB LOSS REPROGRAMS AR AND E2F1 SIGNALING IN MODELS OF PROSTATE CANCER PROGRESSION

11:30 – 12:00 

AM Panel Discussion

12:00 – 12:15

Closing Comments

13:00 – 19:50

Group Trip: Tulum (signups required in advance)

Speakers

Plenary Speakers

Invited Speakers

  • Dr. Sebastiaan Meijsing
    Group leader, Max Planck Institute for Molecular Genetics
  • Prof. Carlie de Vries
    Head of Department, Academic Medical Center, Uni of Amsterdam
  • Dr. Theresa Hickey
    Senior Research Fellow, University of Adelaide
  • Dr. W. Lee Kraus
    Professor and Director, Ut Southwestern Medical Center
  • Dr. Luca Magnani
    Senior Research Fellow, Imperial College London
  • Prof. Philippa Saunders
    Professor, The University of Edinburgh
  • Prof. Susanne Mandrup
    Professor, University of Southern Denmark
  • Prof. Dr. Frank Claessens
    Prof., KU Leuven
  • Prof. David Ray
    Professor of Medicine, University of Manchester
  • Prof. Dr. Steffi Oesterreich
    Professor and Vice Chair, Department of Pharmacology& Chemical Biology, Women's Cancer Research Institute
  • Dr. Jessica Finlay-Schultz
    Associate Professor, University of Colorado Anschutz Medical Campus
  • Dr. Wilbert Zwart
    groupleader, Netherlands Cancer Institute
  • Prof. Dr. Eric Ortlund
    Associate Professor, Emory University
  • Dr. Ganesh Raj
    Professor, UT Southwestern Medical Center
  • Dr. Gordon Hager
    Lab Chief, National Cancer Inst, NIH
  • Dr. Scott Dehm
    Associate Professor, Masonic Cancer Center, University of Minnesota
  • Dr. Charlotte Cornil
    F.R.S.-FNRS Senor Research Associate, Univeristy of Liege
  • Dr. Yijun Ruan
    Professor & Director, JAX Genomic Sciences, The Jackson Laboratory
  • Prof. Dr. Suzanne Conzen
    Professor, The University of Chicago
  • Dr. David VOLLE
    PI, team leader, CNRS UMR 6293, Inserm U1103, UCA
  • Prof. Catherine Williamson
    Professor , King's College London
  • Prof. Eva Estebanez-Perpina
    Professor, University of Barcelona
  • Prof. John Schwabe
    Director of Leicester Institute of Structural and Chemical Biology, University of Leicester

Feedback

Sign In

Your feedback has been received.

Cant see images? See gallery on Flickr